SCHEMBL5452486

SCHEMBL5452486

COc1cccc2c(C(=O)NCc3cccc(Cl)c3)cn(CCCN3CCC(c4nc5ccccc5s4)CC3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 3/20 0.46
PDE10A Q9Y233 1/20 0.45
TP53 P04637 2/20 0.44
POLB P06746 1/20 0.43
UBE2M P61081 4/20 0.42
DCUN1D1 Q96GG9 4/20 0.42
CNR2 P34972 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
GALR3 O60755 1/20 0.42
CHRM4 P08173 1/20 0.41
MEN1 O00255 1/20 0.41
HCRTR1 O43613 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
NOD2 Q9HC29 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446468 0.93 LMNA (0.48) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL14411471 0.88 SMN1; SMN2 (0.51) LMNASMN1; SMN2MAPTTP53POLB
SCHEMBL5448709 0.87 MAPT (0.48) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL5454644 0.86 PDE10A (0.51) PDE10ATP53CNR2ALDH1A1CHRM4
SCHEMBL14410852 0.85 MAPT (0.49) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL14411854 0.85 MAPT (0.42) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL5454189 0.84 MAPT (0.50) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL5443136 0.83 UBE2M (0.48) LMNASMN1; SMN2MAPTTP53UBE2M
SCHEMBL5451298 0.82 PDE10A (0.51) PDE10ACNR2ALDH1A1MEN1KMT2A
SCHEMBL5448407 0.82 PDE10A (0.50) PDE10ACNR2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR LMNA 3791/4885SMN1; SMN2 1701/4885MAPT 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.